These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20143002)

  • 1. [TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic blockade].
    Ursini F
    Reumatismo; 2009; 61(4):254-9. PubMed ID: 20143002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab and insulin resistance.
    Ursini F; Naty S; Grembiale RD
    Autoimmun Rev; 2010 Jun; 9(8):536-9. PubMed ID: 20060507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(1):83-6. PubMed ID: 16539824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome.
    Wascher TC; Lindeman JH; Sourij H; Kooistra T; Pacini G; Roden M
    Mol Med; 2011; 17(3-4):189-93. PubMed ID: 21103669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
    Koutroubakis IE; Oustamanolakis P; Malliaraki N; Karmiris K; Chalkiadakis I; Ganotakis E; Karkavitsas N; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):283-8. PubMed ID: 19279474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes.
    Araújo EP; De Souza CT; Ueno M; Cintra DE; Bertolo MB; Carvalheira JB; Saad MJ; Velloso LA
    Endocrinology; 2007 Dec; 148(12):5991-7. PubMed ID: 17761768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
    LaDuca JR; Gaspari AA
    Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro.
    Méndez-García LA; Trejo-Millán F; Martínez-Reyes CP; Manjarrez-Reyna AN; Esquivel-Velázquez M; Melendez-Mier G; Islas-Andrade S; Rojas-Bernabé A; Kzhyshkowska J; Escobedo G
    Scand J Immunol; 2018 Nov; 88(5):e12716. PubMed ID: 30260514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.
    Miranda-Filloy JA; Llorca J; Carnero-López B; González-Juanatey C; Blanco R; González-Gay MA
    Clin Exp Rheumatol; 2012; 30(6):850-5. PubMed ID: 22765845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.
    Shanahan JC; St Clair W
    Clin Immunol; 2002 Jun; 103(3 Pt 1):231-42. PubMed ID: 12173297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab.
    Di Rocco P; Manco M; Rosa G; Greco AV; Mingrone G
    Obes Res; 2004 Apr; 12(4):734-9. PubMed ID: 15090644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
    Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
    Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation.
    Couriel DR; Hicks K; Giralt S; Champlin RE
    Curr Opin Oncol; 2000 Nov; 12(6):582-7. PubMed ID: 11085458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus.
    Akash MSH; Rehman K; Liaqat A
    J Cell Biochem; 2018 Jan; 119(1):105-110. PubMed ID: 28569437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of infliximab in inflammatory bowel disease.
    Hurd LB; Lichtenstein GR
    Gastroenterol Nurs; 1999; 22(5):199-208. PubMed ID: 10776108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus.
    Zinman B; Hanley AJ; Harris SB; Kwan J; Fantus IG
    J Clin Endocrinol Metab; 1999 Jan; 84(1):272-8. PubMed ID: 9920095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden progression from impaired glucose tolerance to type 2 diabetes after discontinuation of administration of anti-tumor necrosis factor-alpha antibody infliximab.
    Ursini F; Succurro E; Grembiale A; Rudi S; Grembiale RD; Arturi F
    Int J Immunopathol Pharmacol; 2010; 23(3):961-3. PubMed ID: 20943070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.